We are live on ! Find out more

416 hedge funds and large institutions have $7.57B invested in ResMed in 2017 Q4 according to their latest regulatory filings, with 78 funds opening new positions, 152 increasing their positions, 116 reducing their positions, and 25 closing their positions.

New
Increased
Maintained
Reduced
Closed

212% more first-time investments, than exits

New positions opened: 78 | Existing positions closed: 25

79% more call options, than puts

Call options by funds: $10.4M | Put options by funds: $5.8M

31% more repeat investments, than reductions

Existing positions increased: 152 | Existing positions reduced: 116

20% more funds holding in top 10

Funds holding in top 10: 56 (+1)

15% more funds holding

Funds holding: 363416 (+53)

11% more capital invested

Capital invested by funds: $6.84B → $7.57B (+$725M)

0.49% more ownership

Funds ownership: 62.49%62.98% (+0.49%)

Holders
416
Holders Change
+53
Holders Change %
+14.6%
% of All Funds
9.41%
Holding in Top 10
6
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+20%
% of All Funds
0.14%
New
78
Increased
152
Reduced
116
Closed
25
Calls
$10.4M
Puts
$5.8M
Net Calls
+$4.56M
Net Calls Change
-$16.7M

RMD Hedge Fund Activity: Q4 2017 in Review

416 of the 4,419 institutional investors tracked by Wall St. Rank reported a position in ResMed (RMD) for Q4 2017, worth a combined $7.57B — up 11% from $6.84B a quarter earlier.

Buyers outnumbered sellers: 78 funds opened new RMD positions and 25 closed out — a net gain of 53 holders — while 152 added to existing stakes and 116 trimmed.

The largest buyer was Capital World Investors, adding an estimated $130M. The largest seller was Commonwealth Bank of Australia, cutting an estimated $163M.

  • 416 institutional investors held ResMed (RMD) as of Q4 2017, up from 363 in Q3 2017.
  • Funds reported $7.57B of ResMed stock for Q4 2017, up 11% quarter-over-quarter.
  • 78 funds opened new ResMed positions in Q4 2017 and 25 closed out, a net change of +53 holders.
  • The largest ResMed buyer in Q4 2017 was Capital World Investors, an estimated $130M added.
  • The largest ResMed seller in Q4 2017 was Commonwealth Bank of Australia, an estimated $163M sold.

Based on aggregated 13F filings for Q4 2017.